MediciNova (MNOV) tacks on an additional 12.4% gain from yesterday's big move, after the company...

|By:, SA News Editor

MediciNova (MNOV) tacks on an additional 12.4% gain from yesterday's big move, after the company said its MN-166 drug treatment for methamphetamine dependence has been granted fast-track status by the FDA.